ArticleJournal of translational medicine2026
IGFBP2 promotes immunosuppression by regulating macrophage PD-L1 expression in NEUROD1-high small cell lung cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe 5-year survival rate for small cell lung cancer (SCLC) remains low. Immune tolerance is a significant characteristic of this disease and plays a crucial role in its malignant progression. Insulin-like Growth Factor Binding Protein 2 (IGFBP2) has attracted widespread attention as a potential therapeutic target in cancer, but its role in SCLC remains to be elucidated.
methodsThis study investigated the association between IGFBP2 secreted by NEUROD1-high small cell lung cancer (SCLC-N) and the expression of programmed cell death ligand 1 (PD-L1) in tumor associated macrophages (TAMs) using multiplex immunohistochemistry (mIHC), western blotting (WB), quantitative PCR (qPCR) and immunofluorescence (IF) following co-culture TAMs with SCLC cells. The infiltration and exhaustion of CD8 + T lymphocytes were detected using qPCR, mIHC, flow cytometry and ELISA. Subcutaneous syngeneic model using Lewis lung carcinoma (LLC) cells employed to elucidate the functions of IGFBP2. The upstream regulation mode of IGFBP2 high expression in SCLC-N was explored through integrated analysis of ChIP-seq and CUT&Tag data. Furthermore, the mechanism by which IGFBP2 promotes PD-L1 expression in TAMs was defined by constructing wild-type (WT) and NLSmutant (MUT) IGFBP2 overexpression plasmids.
resultsThis study reveals that IGFBP2 is upregulated in SCLC-N cell lines and tissues. Furthermore, high IGFBP2 expression in SCLC-N promotes the shift of TAMs toward M2-type TAMs (M2-TAMs) and induces PD-L1 expression. This IGFBP2-induced PD-L1 elevation in TAMs correlates with reduced CD8 + T cell infiltration and enhanced T-cell exhaustion. Functionally, in vivo administration of recombinant IGFBP2 promotes tumor growth and attenuates the efficacy of PD-L1 inhibitors. Mechanistically, NEUROD1 directly binds to the IGFBP2 promoter and activates its expression in SCLC-N. Moreover, nuclear translocation of IGFBP2 is required for promoting PD-L1 expression in TAMs.
conclusionsOur research supports the idea that IGFBP2 secreted by SCLC-N cells stimulates immunosuppression via promoting the PD-L1 expression in TAMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.